NCT04183452View on ClinicalTrials.gov

17-OHPC in Pregnancy: IM vs SC Routes

TerminatedOBSERVATIONAL
Enrollment

24

Participants

Timeline

Start Date

June 16, 2020

Primary Completion Date

April 6, 2023

Study Completion Date

April 6, 2023

Conditions
Preterm Birth
Interventions
DRUG

17-Hydroxyprogesterone Caproate 250 mg IM Dose

17-Hydroxyprogesterone Caproate is a progestin indicated to reduce the risk of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth.

DRUG

17-Hydroxyprogesterone Caproate 275 mg SC Dose

17-Hydroxyprogesterone Caproate is a progestin indicated to reduce the risk of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth

Trial Locations (4)

15213

University of Pittsburgh-Magee Womens Hospital, Pittsburgh

19713

Christiana Care, Newark

27157

Wake Forest Baptist Medical Center, Winston-Salem

27710

Duke University Medical Center, Durham

Sponsors
All Listed Sponsors
collaborator

AMAG Pharmaceuticals, Inc.

INDUSTRY

lead

Steve N. Caritis, MD

OTHER